Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. For over ten years, the Company has been an innovator of technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. monoclonal antibodies, growth factors, enzymes). From discovery to late-phase clinical trials, Selexis’ technology has been and is currently being used by more than 100 companies worldwide. Selexis addresses critical issues in the development of clonal cell lines for protein manufacturing while providing innovative and reliable approaches to drug discovery. The Selexis SUREtechnology Platform™ can be applied to R&D, Bio Production, Preclinical Production, Target Discovery, Cell Based Assays and Diagnostics.
INDUSTRIES
• Bioproduction (biologics manufacturing)
• Biopharmaceuticals
• Biotechnology
• Cell line development for protein manufacturing
• Cell therapies
• Contract manufacturing
• Clinical research
• Diagnostics
• Pharmaceutical
• Vaccines
APPLICATIONS
• R&D
• Bioproduction
• Preclinical Production
• Target Discovery
• Cell Based Assays
• Diagnostics
Specialties
Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening
